VIP

Investigational

Also known as: Vasoactive Intestinal Peptide, Aviptadil

Immune & Respiratory

Last reviewed: April 28, 2026

A 28-amino-acid neuropeptide naturally produced throughout the body, with particularly high concentrations in the gut, lungs, and nervous system. VIP has potent anti-inflammatory, vasodilatory, and immunomodulatory properties. It gained significant attention during COVID-19 as aviptadil (synthetic VIP) was studied for acute respiratory distress. In integrative medicine, it is widely used for chronic inflammatory response syndrome (CIRS) and mold illness protocols.

Mechanism of Action

Binds to VPAC1 and VPAC2 receptors, activating cAMP-dependent pathways that suppress pro-inflammatory cytokines (TNF-α, IL-6, IL-12) while promoting anti-inflammatory cytokines (IL-10). Also acts as a potent vasodilator, bronchodilator, and neuroprotective agent. In the lungs, VIP protects alveolar type II cells from inflammatory damage.

Common Uses

  • Chronic inflammatory response syndrome (CIRS)
  • Mold illness treatment (Shoemaker protocol)
  • Pulmonary hypertension
  • Neuroinflammation
  • GI motility disorders

Known Risks

  • Hypotension (due to vasodilation)
  • Diarrhea at higher doses
  • Nasal irritation with intranasal use
  • Flushing and headache
  • Limited standardized clinical data for CIRS indication

Regulatory Status

Investigational

Aviptadil (synthetic VIP) has been studied in clinical trials for ARDS and pulmonary hypertension. Not FDA-approved for any indication. Used off-label by integrative medicine practitioners for CIRS. The Shoemaker CIRS protocol includes intranasal VIP as a final step, though this use is not FDA-sanctioned.

Common Protocols

Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.

Intranasal spray

Typical Dose

50 mcg per nostril (Shoemaker protocol)

Frequency

4 times daily

Cycle Length

30 days minimum, often longer

The Shoemaker CIRS protocol uses intranasal VIP as the final treatment step after other markers are normalized. Must be compounded by a specialty pharmacy. Some practitioners also use subcutaneous injection. Store refrigerated. VIP is fragile — proper handling is critical.

Related Compounds

Research References

This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.